FDA Approval: MARIPOSA2, Amivantamab plus Chemotherapy after Osimertinib for EGFR NSCLC

Podcast | English | 2024 | 23 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about this research and how the therapy will be used by clinicians.

Podcast Host:

Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Karen Reckamp, MD, MS, Clinical Professor in the Department of Medicine, Cedars-Sinai Medcial Center, Los Angeles, CA, USA
William Nassib William, MD, National Leader of Thoracic Oncology, Oncolinicas, Sao Paulo, Brazil